NASDAQ: VRCA - Verrica Pharmaceuticals Inc.

Rentabilität für sechs Monate: -69.83%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Verrica Pharmaceuticals Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

weitere details
It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2018-06-15
ISIN US92511W1080
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.verrica.com
Цена ао 0.445
Preisänderung pro Tag: -0.1142% (0.438)
Preisänderung pro Woche: -21.59% (0.558)
Preisänderung pro Monat: -38.38% (0.71)
Preisänderung über 3 Monate: -36.04% (0.684)
Preisänderung über sechs Monate: -69.83% (1.45)
Preisänderung pro Jahr: -92.61% (5.92)
Preisänderung über 3 Jahre: -94.75% (8.33)
Preisänderung über 5 Jahre: -96.46% (12.37)
Preisänderung seit Jahresbeginn: -42.51% (0.761)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 57.52 1
P/BV 14.91 1
P/E 0 0
EV/EBITDA -4.34 0
Gesamt: 2.75

Effizienz

Name Bedeutung Grad
ROA, % -82.1 0
ROE, % -338.99 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.6985 10
Gesamt: 8.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -57.3 0
Rentabilität Ebitda, % 106.63 10
Rentabilität EPS, % 40.72 6
Gesamt: 6.2
Weitere Details

Institutionen Volumen Aktie, %
Perceptive Advisors LLC 5038983 11.98
Avoro Capital Advisors LLC 2954064 7.02
FMR, LLC 1504716 3.58
Vanguard Group Inc 1226858 2.92
Blackrock Inc. 1051050 2.5
Geode Capital Management, LLC 416790 0.99
State Street Corporation 382743 0.91
Caligan Partners, LP 259593 0.62
Northern Trust Corporation 187478 0.45
Boxer Capital, LLC 166955 0.4



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Ted White President, CEO & Director 772.77k 1965 (60 Jahre)
Dr. Gary Goldenberg M.D. Chief Medical Officer 553.03k 1977 (48 Jahre)
Mr. P. Terence Kohler Chief Financial Officer N/A
Mr. Christopher G. Hayes Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel N/A 1964 (61 Jahr)
Mr. Eugene Scavola Executive Vice President of Technical Operations N/A
Dr. Bradley J. Catalone MBA, Ph.D. Head of Drug Development N/A

Adresse: United States, West Chester. PA, 44 West Gay Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.verrica.com